Phase 4 N=160 Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis
Tendonitis
Primary: Opioid Utilization for the First 24 Hours After Surgery — 17.5; 20 morphine milligram equivalents
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=152 A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Type 2 Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.43 Percentage of HbA1c
Phase 4 N=34 Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Relapsing Multiple Sclerosis
Primary: Percentage of Participants Having Established SARS-CoV-2-specific T Cells After Receiving a modRNA Vaccine — 80.0; 87.5; 100.0; 46.7 percentage of participants
Phase 4 N=27 Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
Pleural Effusion
Primary: Chest X-ray Results on Day 3 After Pleurodesis — 5; 6; 5; 8 Participants — p=0.863
Phase 4 N=139 FAsenra Safety Trial in India
In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
Primary: Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs — 44; 5; 43; 1 Participants
Phase 4 N=129 Pre-incision Versus Post-incision Local Anesthetic During Robotic Sacrocolpopexy
Pain, Postoperative
Primary: Likert-pain Scale Score on Postoperative Day One — 2.94; 3.27 units on a scale
Phase 4 N=60 SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty
Surgery · Surgical Site Infection · Cutibacterium Acnes
Primary: Presence of Bacteria Within Shoulder Culture Using Incisional Prep vs. no Prep — 11; 9; 6 Participants — p=0.275
Phase 4 N=94 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
COVID-19 · Venous Thromboses · Arterial Thrombosis
Primary: Total Number of Patients Who Were Alive and Without Venous/Thrombotic Events in ICU — 28; 31 Participants
Phase 4 N=105 Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration (nAMD)
Primary: Incidence and Characteristics of Treatment-emergent Adverse Events During the 56 Weeks of Treatment With Brolucizumab. — 67; 50; 45; 9 Participants
Phase 4 N=100 Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
Asthma
Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) — 3; 9 Participants
Phase 4 N=44,618 Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV)
Pneumococcal Carriage
Primary: Effect of a Single Dose PCV10 Campaign in the Reduction of VT Carriage — 4.6; 8.0; 16.5 Percentage of participants
Phase 4 N=23 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Glucose Intolerance · Overweight and Obesity · Drug Effect
Primary: Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue) — 7.88; 7.67 natural log(arbitrary units)
Phase 4 N=25 Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
Atrial Fibrillation
Primary: Mean Percentage of Time Spent in Atrial Fibrillation — 2.74; 5.85 percentage of time
Phase 4 N=54 Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
Gestational Diabetes · Diabetes, Gestational · Pregnancy in Diabetes
Primary: Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study — 25; 26 Participants — p=0.9
Phase 4 N=82 Seizure Prophylaxis in Aneurysm Repair
Intracranial Aneurysms · Seizure
Primary: Incidence of Seizure — 2; 1; 0; 0 Participants